Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vertex Pharmaceuticals
Biotech
Vertex takes $379M hit tied to cancelled islet cell program
Vertex announced a $379 million impairment charge tied to its earlier discontinuation of a clinical-stage islet cell treatment for diabetes.
Gabrielle Masson
May 6, 2025 12:50pm
Vertex discontinues AAV research for gene therapies
May 2, 2025 6:22pm
Vertex drops cell-device diabetes combo over poor ph. 1 results
Mar 31, 2025 4:20am
Vertex axes Verve gene editing pact amid shift in R&D priorities
Feb 27, 2025 9:05am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
